Your browser doesn't support javascript.
loading
Copeptin as a marker of atherosclerosis and arteriosclerosis.
Schill, Fredrika; Persson, Margaretha; Engström, Gunnar; Melander, Olle; Enhörning, Sofia.
  • Schill F; Department of Cardiology, Skåne University Hospital, Carl-Bertil Laurells gata 9, 214 28, Malmö, Sweden; Department of Clinical Sciences, Lund University, Jan Waldenströms gata 35, 214 28, Malmö, Sweden. Electronic address: Fredrika.Schill@med.lu.se.
  • Persson M; Department of Clinical Sciences, Lund University, Jan Waldenströms gata 35, 214 28, Malmö, Sweden; Department of Internal Medicine, Skåne University Hospital, Jan Waldenströms gata 11 A, 214 28, Malmö, Sweden.
  • Engström G; Department of Clinical Sciences, Lund University, Jan Waldenströms gata 35, 214 28, Malmö, Sweden.
  • Melander O; Department of Clinical Sciences, Lund University, Jan Waldenströms gata 35, 214 28, Malmö, Sweden; Department of Internal Medicine, Skåne University Hospital, Jan Waldenströms gata 11 A, 214 28, Malmö, Sweden.
  • Enhörning S; Department of Clinical Sciences, Lund University, Jan Waldenströms gata 35, 214 28, Malmö, Sweden; Department of Internal Medicine, Skåne University Hospital, Jan Waldenströms gata 11 A, 214 28, Malmö, Sweden.
Atherosclerosis ; 338: 64-68, 2021 12.
Article en En | MEDLINE | ID: mdl-34785062
ABSTRACT
BACKGROUND AND

AIMS:

The precursor peptide of vasopressin, copeptin, has previously been linked to increased risk of developing diabetes mellitus, coronary artery disease and cardiovascular mortality. Whether elevated copeptin is associated with markers of atherosclerosis and arteriosclerosis in the general population is not known.

METHODS:

In this population-based, cross-sectional study, coronary artery calcium score (CACS), carotid-femoral pulse wave velocity (c-f PWV) and fasting plasma copeptin were measured in 5303 individuals in the Swedish cardiopulmonary bioimage study (SCAPIS). Multivariable logistic regression models were used to analyze the associations between copeptin and high CACS (>100) and high c-f PWV (>10 m/s), respectively.

RESULTS:

The number of individuals with high CACS and c-f PWV increased across increasing tertile of copeptin (11.7%, 13.3% and 16.3% for CACS and 6.9%, 8.5% and 10.6% for c-f PWV). The top tertile of copeptin was, compared with reference tertile 1, significantly associated with both high CACS and high c-f PWV after adjustment for age, sex, hypertension, diabetes mellitus, HDL, triglycerides, BMI, smoking status, creatinine and high sensitive CRP with an odds ratio (OR) of 1.260 (95% confidence interval (CI) 1.022-1.555) for CACS and OR 1.389 (95% CI 1.069-1.807) for PWV.

CONCLUSIONS:

Copeptin is associated with both coronary atherosclerosis and increased arterial stiffness in the general population. Our data indicates that copeptin may be a useful marker in the assessment of cardiovascular risk.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Aterosclerosis / Rigidez Vascular Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Aterosclerosis / Rigidez Vascular Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article